| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
AMPA receptors (AMPARs), specifically the GluA2 subunit (GluA2i and GluA2o isoforms). The compound is a positive allosteric modulator that enhances receptor activity by binding at the interdimer interface.
|
|---|---|
| ln Vitro |
CMPDA increases glutamate-induced calcium influx into HEK293 cells expressing human GluA2i or GluA2o receptors. The compound shows EC50 values of 45.4 +/- 4.2 nM for GluA2i and 63.4 +/- 5.6 nM for GluA2o receptors in calcium influx screening assays. It demonstrates potent modulatory activity at nanomolar concentrations.
|
| ln Vivo |
No specific in vivo activity data is available for CMPDA. As a positive allosteric modulator of AMPA receptors, it is primarily studied in vitro for its receptor-binding properties and calcium influx modulation. AMPA receptor modulators are generally investigated for their potential in neurological research and cognitive enhancement.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for CMPDA typically involves calcium influx screening in HEK293 cells expressing human GluA2i or GluA2o receptors. Cells are pre-incubated with the compound, and glutamate-induced calcium influx is measured using calcium-sensitive fluorescent dyes. The EC50 values are determined from dose-response curves. Binding occurs at the modulator binding pocket located at the interdimer interface.
|
| Cell Assay |
The in vitro cellular assay for CMPDA uses HEK293 cells transfected to express human GluA2i or GluA2o AMPA receptors. Cells are loaded with a calcium indicator dye, and the increase in intracellular calcium in response to glutamate stimulation is measured in the presence of varying concentrations of the test compound. The EC50 for potentiation of calcium influx is calculated from the concentration-response curves.
|
| Animal Protocol |
No specific in vivo animal experimental protocols are available for CMPDA. As a research tool for studying AMPA receptor modulation, its primary applications are in vitro. For in vivo studies, AMPA receptor modulators are typically administered via intraperitoneal or oral routes in rodent models to assess effects on cognition, seizure threshold, or neurological function, with dosing regimens depending on the specific experimental endpoints.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is available for CMPDA. Based on its chemical properties (molecular weight 376.53 g/mol, formula C16H28N2O4S2), it is expected to have moderate lipophilicity and potential for blood-brain barrier penetration given its target is a central nervous system receptor. AMPA receptor modulators typically require optimization for oral bioavailability and CNS exposure.
|
| Toxicity/Toxicokinetics |
No specific toxicological data is available for CMPDA. As a research compound intended for laboratory use, standard safety precautions should be observed. No clinical toxicity studies have been reported. The compound has not been evaluated for genotoxicity, carcinogenicity, or reproductive toxicity.
|
| References | |
| Additional Infomation |
CMPDA is a research tool for studying AMPA receptor pharmacology and glutamatergic signaling. It is not approved for clinical use and is intended for laboratory research only. The compound is supplied as a 10 mM solution or in powder form. Its mechanism of action involves positive allosteric modulation of AMPA receptors, enhancing glutamate-induced calcium influx without directly activating the receptor. It is part of a class of compounds used to study synaptic plasticity and neurological disorders.
|
| Molecular Formula |
C16H28N2O4S2
|
|---|---|
| Molecular Weight |
376.53452205658
|
| Exact Mass |
376.149
|
| CAS # |
380607-77-2
|
| PubChem CID |
9969799
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.37
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
24
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=CC(=C1)C2=C(N=C3N2C(=CC=C3)OC)C(=O)N(CCN(C)C)C4CS(=O)(=O)C5=C4C=CC(=C5C#N)C(F)(F)F)F
|
| InChi Key |
FHLGMMYEKXPVSC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H28N2O4S2/c1-13(2)23(19,20)17-11-9-15-5-7-16(8-6-15)10-12-18-24(21,22)14(3)4/h5-8,13-14,17-18H,9-12H2,1-4H3
|
| Chemical Name |
N-[2-[4-[2-(propan-2-ylsulfonylamino)ethyl]phenyl]ethyl]propane-2-sulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~265.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6558 mL | 13.2792 mL | 26.5583 mL | |
| 5 mM | 0.5312 mL | 2.6558 mL | 5.3117 mL | |
| 10 mM | 0.2656 mL | 1.3279 mL | 2.6558 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
